“The existing scenario has exposed some structural weaknesses while in the EU’s medicines source chain and also a superior dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides said. She proposed that provide chain troubles be dealt with within an EU pharmaceutical approa